Food businesses are rapidly adapting to a significant shift in consumer appetite driven by the increasing use of GLP-1 drugs like Ozempic and Wegovy. A majority of consumers now report modifying their orders, with the most common changes being smaller portion sizes, prioritising high-protein items, and including more vegetables in their meals.
Consumer Behavior Under GLP-1 Influence
According to a 2025 report by Business Insider, the rise of GLP-1 receptor agonists—originally developed for diabetes management—has led to a notable decrease in cravings and overall food intake among users. This has prompted food companies to rethink product formulations, packaging, and marketing strategies.
Data from RaboResearch indicates that packaging substrates across grocery categories are being redesigned to accommodate smaller, more frequent meal options. Companies like Nestle are reportedly exploring product lines tailored to the nutritional needs of GLP-1 users, focusing on high-protein, low-carb, and nutrient-dense offerings.
Industry Response to Appetite Shift
The food sector is witnessing a pivot toward portion-controlled packaging and functional foods that align with the reduced appetite and altered taste preferences of consumers on these medications. A spokesperson for a major food manufacturer noted, "We are seeing a clear trend where customers are seeking out products that support satiety and muscle maintenance, which has accelerated our innovation in high-protein snacks and meal replacements."
Retailers are also adjusting shelf space to feature more ready-to-eat, protein-rich items. Smaller portion sizes are becoming standard, with some brands introducing mini-meal packs designed for those with lower caloric needs.
Long-Term Implications for Food Business
Analysts predict that the impact of GLP-1 drugs on eating habits will persist, potentially reshaping the food industry for years to come. A 2025 study cited in the report found that 65% of users reduced their grocery spending, while 40% changed their preferred food categories. This has led to a surge in demand for products that are both convenient and nutritionally optimized.
As more consumers adopt these medications for weight management, food businesses are expected to continue innovating, with a focus on personalized nutrition and portion control. The shift underscores a broader transformation in how the industry addresses appetite and dietary needs in the era of pharmacological intervention.
